Cargando…

Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats

Previous studies have demonstrated that pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, inhibits ischemia-induced brain injury. The present study was conducted to examine whether pioglitazone can reduce impairment of behavioral deficits mediated by inflammatory-indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Jiann-Horng, Wang, Kuo-Ching, Kaizaki, Asuka, Lee, Jonathan W., Wei, Han-Chi, Tucci, Michelle A., Ojeda, Norma B., Fan, Lir-Wan, Tien, Lu-Tai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231261/
https://www.ncbi.nlm.nih.gov/pubmed/34208374
http://dx.doi.org/10.3390/ijms22126306
_version_ 1783713390587281408
author Yeh, Jiann-Horng
Wang, Kuo-Ching
Kaizaki, Asuka
Lee, Jonathan W.
Wei, Han-Chi
Tucci, Michelle A.
Ojeda, Norma B.
Fan, Lir-Wan
Tien, Lu-Tai
author_facet Yeh, Jiann-Horng
Wang, Kuo-Ching
Kaizaki, Asuka
Lee, Jonathan W.
Wei, Han-Chi
Tucci, Michelle A.
Ojeda, Norma B.
Fan, Lir-Wan
Tien, Lu-Tai
author_sort Yeh, Jiann-Horng
collection PubMed
description Previous studies have demonstrated that pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, inhibits ischemia-induced brain injury. The present study was conducted to examine whether pioglitazone can reduce impairment of behavioral deficits mediated by inflammatory-induced brain white matter injury in neonatal rats. Intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 2 mg/kg) was administered to Sprague–Dawley rat pups on postnatal day 5 (P5), and i.p. administration of pioglitazone (20 mg/kg) or vehicle was performed 5 min after LPS injection. Sensorimotor behavioral tests were performed 24 h after LPS exposure, and changes in biochemistry of the brain was examined after these tests. The results show that systemic LPS exposure resulted in impaired sensorimotor behavioral performance, reduction of oligodendrocytes and mitochondrial activity, and increases in lipid peroxidation and brain inflammation, as indicated by the increment of interleukin-1β (IL-1β) levels and number of activated microglia in the neonatal rat brain. Pioglitazone treatment significantly improved LPS-induced neurobehavioral and physiological disturbances including the loss of body weight, hypothermia, righting reflex, wire-hanging maneuver, negative geotaxis, and hind-limb suspension in neonatal rats. The neuroprotective effect of pioglitazone against the loss of oligodendrocytes and mitochondrial activity was associated with attenuation of LPS-induced increment of thiobarbituric acid reactive substances (TBARS) content, IL-1β levels and number of activated microglia in neonatal rats. Our results show that pioglitazone prevents neurobehavioral disturbances induced by systemic LPS exposure in neonatal rats, and its neuroprotective effects are associated with its impact on microglial activation, IL-1β induction, lipid peroxidation, oligodendrocyte production and mitochondrial activity.
format Online
Article
Text
id pubmed-8231261
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82312612021-06-26 Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats Yeh, Jiann-Horng Wang, Kuo-Ching Kaizaki, Asuka Lee, Jonathan W. Wei, Han-Chi Tucci, Michelle A. Ojeda, Norma B. Fan, Lir-Wan Tien, Lu-Tai Int J Mol Sci Article Previous studies have demonstrated that pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, inhibits ischemia-induced brain injury. The present study was conducted to examine whether pioglitazone can reduce impairment of behavioral deficits mediated by inflammatory-induced brain white matter injury in neonatal rats. Intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 2 mg/kg) was administered to Sprague–Dawley rat pups on postnatal day 5 (P5), and i.p. administration of pioglitazone (20 mg/kg) or vehicle was performed 5 min after LPS injection. Sensorimotor behavioral tests were performed 24 h after LPS exposure, and changes in biochemistry of the brain was examined after these tests. The results show that systemic LPS exposure resulted in impaired sensorimotor behavioral performance, reduction of oligodendrocytes and mitochondrial activity, and increases in lipid peroxidation and brain inflammation, as indicated by the increment of interleukin-1β (IL-1β) levels and number of activated microglia in the neonatal rat brain. Pioglitazone treatment significantly improved LPS-induced neurobehavioral and physiological disturbances including the loss of body weight, hypothermia, righting reflex, wire-hanging maneuver, negative geotaxis, and hind-limb suspension in neonatal rats. The neuroprotective effect of pioglitazone against the loss of oligodendrocytes and mitochondrial activity was associated with attenuation of LPS-induced increment of thiobarbituric acid reactive substances (TBARS) content, IL-1β levels and number of activated microglia in neonatal rats. Our results show that pioglitazone prevents neurobehavioral disturbances induced by systemic LPS exposure in neonatal rats, and its neuroprotective effects are associated with its impact on microglial activation, IL-1β induction, lipid peroxidation, oligodendrocyte production and mitochondrial activity. MDPI 2021-06-11 /pmc/articles/PMC8231261/ /pubmed/34208374 http://dx.doi.org/10.3390/ijms22126306 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yeh, Jiann-Horng
Wang, Kuo-Ching
Kaizaki, Asuka
Lee, Jonathan W.
Wei, Han-Chi
Tucci, Michelle A.
Ojeda, Norma B.
Fan, Lir-Wan
Tien, Lu-Tai
Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats
title Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats
title_full Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats
title_fullStr Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats
title_full_unstemmed Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats
title_short Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats
title_sort pioglitazone ameliorates lipopolysaccharide-induced behavioral impairment, brain inflammation, white matter injury and mitochondrial dysfunction in neonatal rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231261/
https://www.ncbi.nlm.nih.gov/pubmed/34208374
http://dx.doi.org/10.3390/ijms22126306
work_keys_str_mv AT yehjiannhorng pioglitazoneameliorateslipopolysaccharideinducedbehavioralimpairmentbraininflammationwhitematterinjuryandmitochondrialdysfunctioninneonatalrats
AT wangkuoching pioglitazoneameliorateslipopolysaccharideinducedbehavioralimpairmentbraininflammationwhitematterinjuryandmitochondrialdysfunctioninneonatalrats
AT kaizakiasuka pioglitazoneameliorateslipopolysaccharideinducedbehavioralimpairmentbraininflammationwhitematterinjuryandmitochondrialdysfunctioninneonatalrats
AT leejonathanw pioglitazoneameliorateslipopolysaccharideinducedbehavioralimpairmentbraininflammationwhitematterinjuryandmitochondrialdysfunctioninneonatalrats
AT weihanchi pioglitazoneameliorateslipopolysaccharideinducedbehavioralimpairmentbraininflammationwhitematterinjuryandmitochondrialdysfunctioninneonatalrats
AT tuccimichellea pioglitazoneameliorateslipopolysaccharideinducedbehavioralimpairmentbraininflammationwhitematterinjuryandmitochondrialdysfunctioninneonatalrats
AT ojedanormab pioglitazoneameliorateslipopolysaccharideinducedbehavioralimpairmentbraininflammationwhitematterinjuryandmitochondrialdysfunctioninneonatalrats
AT fanlirwan pioglitazoneameliorateslipopolysaccharideinducedbehavioralimpairmentbraininflammationwhitematterinjuryandmitochondrialdysfunctioninneonatalrats
AT tienlutai pioglitazoneameliorateslipopolysaccharideinducedbehavioralimpairmentbraininflammationwhitematterinjuryandmitochondrialdysfunctioninneonatalrats